INS and type 2 diabetes mellitus: ONWARDS 2 (NCT04770532) was a randomized, open-label, treat-to-target, 26-week trial including 526 T2DM patients previously treated with basal insulin, with or without non-insulin anti-diabetic treatment (except SUs or glinides), who switched to once-weekly insulin icodec versus those who switched to once-daily insulin degludec.